Consumer Goods - Germany



Buy (old: Buy) 29.01.2025

EUR 17.00 (old: EUR 17.00)

Trading update confirms guidance reach at upper end; chg. est

Topic: WEW released a FY'24 trading update which points towards a sales and adj. EBITDA guidance reach at the upper end for both despite a muted consumer sentiment. In detail:

FY'24 GMV was reported up 3.3% yoy at € 497m (eNuW: € 486m) which should have been the result of a continuation of a growing avg. basket size (eNuW: +11% yoy) and a return in growth of active customers (eNuW: +2% yoy), but dampened by a decline in number of orders (eNuW: - 7% yoy). As sales develop mostly proportionate to GMV, this would imply FY'24 sales of € 443m (eNuW old: € 435m), which stands at the top-end of the € 415-445m guidance range.

Consequently, WEW also specified its adj. EBITDA guidance towards the upper end of the € 14-24m range (eNuW old: € 18m, eNuW new: € 20m, 4.5% adj. EBITDA margin). Here, we also expect the positive trend of an improving cost mix visible in Q1-Q3'24 to have positively affected profitability in Q4. The main driver should have been the improved gross margin (eNuW: +0.8% yoy) thanks to a higher private label share of 55% in FY'24 (58% in Q4'24).


Also positively, WEW reported a positive FCF of € 9m for FY'24e (eNuW old: € 2m), which implies a Q4'24 FCF of € 20m which should stem from a large inventory reduction. Consequently, the strong net cash position stood at € 69m (eNuW old: € 58m), despite the € 10m share buyback program executed in Nov'24


Outlook 2025: Thanks to a still ongoing muted consumer sentiment, we do not expect a major demand swingback for WEW. Consequently, sales is seen to grow by 3.4% yoy to € 458m in FY'25e. For profitability, we expect a 0.4pp yoy margin improvement to an adj. EBITDA of € 23m, carried by a rising contribution margin as a further rising private label share should support a stronger gross margin (eNuW: +0.8pp yoy).


In sum a solid release, showing that WEW maintained profitable growth with positive FCFs despite a muted consumer sentiment, assortment changes, restructuring expenses and the SaaS platform transformation. Against this backdrop, we reiterate our BUY recommendation with unchanged PT of € 17.00, based on DCF.

| Y/E 31.12 (EUR m) | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
|--------------------------|-------|--------|-------|--------|-------|-------|
| Sales | 522.5 | 430.8 | 428.7 | 443.0 | 457.9 | 502.1 |
| Sales growth | 20.7% | -17.6% | -0.5% | 3.3% | 3.4% | 9.7% |
| Adj. EBITDA | 40.4 | -4.2 | 17.8 | 20.1 | 22.5 | 32.0 |
| Net debt (if net cash=0) | -87.1 | -56.2 | -82.0 | -68.6 | -69.0 | -77.2 |
| FCF | 3.8 | -21.4 | 29.5 | 9.0 | 7.4 | 15.2 |
| Net Debt/EBITDA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EPS pro forma | 0.55 | -1.51 | -0.61 | -0.56 | -0.11 | 0.27 |
| Adj. EBITDA margin | 7.7% | -1.0% | 4.2% | 4.5% | 4.9% | 6.4% |
| ROCE | 22.2% | -23.5% | -9.0% | -14.0% | -2.7% | 9.6% |
| EV/sales | 1.4 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 |
| EV/EBITDA | 17.9 | -27.5 | 4.8 | 4.4 | 4.1 | 2.6 |
| PER | 67.5 | -5.2 | -13.0 | -14.0 | -73.3 | 29.3 |
| Adjusted FCF yield | 3.0% | -13.6% | 4.3% | 1.0% | 10.7% | 19.8% |

Source: Company data, NuWays, Close price as of 24.01.2025







ROCE (2021-26e)

| | Sile | ire P | eriori | nanc | e | |
|------|-------------|----------|----------|----------|----------------------|---------------|
| 8.60 | | | | | | |
| 8.40 | | Λ. Α | | 1 | | |
| 8.20 | Α | M^{-1} | ν. | <u> </u> | A | |
| 8.00 | | γľ | \ | | $-\Lambda_{\Lambda}$ | |
| 7.80 | 11 /\ll\/v | | ١. | 4 | / V | |
| 7.60 | 144 | | $-\nu M$ | 1.1 | | - |
| 7.40 | | | | M | | eq |
| 7.20 | | | | - 4 | W | \rightarrow |
| 7.00 | | | | | | _ |
| | 03/24 | 05/24 | 07/24 | 09/24 | 11/24 | 01/25 |
| | | | | | | |
| Hig | h/low 52 | week | S (€) | 8 | 3.54 / | 7.08 |
| | rel. perfo | | | | -3 | .6% |
| | rel. perfe | | | | | .2% |
| | n rel. per | | | | | .6% |
| 121 | ii ici. pci | 1011110 | 1100 | | -0 | .0 /0 |

| iviai ket uata | |
|-----------------------------|-------|
| Share price (in €) | 7.18 |
| Market cap (in € m) | 158.8 |
| Number of shares (in m pcs) | 20.1 |
| Enterprise value (in € m) | 91.9 |
| Ø trading volume (6 months) | 7,200 |

Market data

| | ldentifier |
|-----------|--------------|
| Bloomberg | WEW GR |
| Reuters | WEW |
| WKN | A2N4H0 |
| ISIN | DE000A2N4H07 |

| Key shareholders | | | | |
|-------------------|-------|--|--|--|
| Zerena | 28.9% | | | |
| Amiral Gestion | 9.9% | | | |
| The Capital Group | 7.6% | | | |
| Aymeric Chaumet | 5.7% | | | |
| Bram Cornelisse | 5.3% | | | |
| Free Float | 10.2% | | | |

| Estimates changes | | | | | | |
|-------------------|--------------|--------------|--------------|--|--|--|
| | <u>2024e</u> | <u>2025e</u> | <u>2026e</u> | | | |
| Sales | 2% | 1% | -0% | | | |
| EBIT | 17% | -1% | -0% | | | |
| EPS | 18% | -1% | -0% | | | |

Comment on changes

Guidance

2024 Sales: -3% to +4% yoy

2022

2024 Adj. EBITDA: € 14-24m

2023

2024e

2025e

Company description

Westwing is a leading e-commerce platform that allows customers to have the combined advantages of online and offline shops for home and living products. The company's product portfolio is complemented by consultation services from professional designers.

Update - 29.01.2025



Financials

| Profit and lose (EUD m) | 2024 | 2022 | 2022 | 20246 | 20250 | 2026 |
|---|--|---|--|---|--|--|
| Profit and loss (EUR m) Sales | 2021 522.5 | 2022 430.8 | 2023 428.7 | 2024e 443.0 | 2025e 457.9 | 2026e 502.1 |
| Sales growth | 20.7% | -17.6% | -0.5% | 3.3% | 3.4% | 9.7% |
| Cost of sales | 265.7 | 228.1 | 215.7 | 219.2 | 223.1 | 243.1 |
| Gross profit | 256.8 | 202.7 | 213.0 | 223.8 | 234.8 | 259.0 |
| Sales and marketing | 156.4 | 134.8 | 135.8 | 143.6 | 146.5 | 158.2 |
| General and administration | 79.3 | 92.9 | 85.3 | 88.0 | 87.4 | 90.9 |
| Research and development | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other operating income | 3.9 | 2.8 | 5.9 | 4.8 | 2.7 | 3.0 |
| Other operating expenses | 3.8 | 5.2 | 6.2 | 7.5 | 5.5 | 5.0 |
| EBITDA | 40.4 | -9.4 | 11.4 | 11.4 | 16.1 | 25.0 |
| Unusual or infrequent items | 6.2 | 0.0 | 6.4 | 8.7 | 6.4 | 7.0 |
| Adj. EBITDA | 40.4 | -4.2 | 17.8 | 20.1 | 22.5 | 32.0 |
| Depreciation | 9.2 | 12.2 | 13.2 | 14.6 | 10.8 | 9.4 |
| Amortisation of goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Amortisation of intangible assets | 3.8 | 5.8 | 6.6 | 7.3 | 7.2 | 7.6 |
| Impairment charges | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| EBIT (inc revaluation net) | 27.4 | -27.4 | -8.4 | -10.5 | -1.9 | 8.0 |
| Interest income | 0.0 | 0.0 | 1.1 | 1.8 | 1.4 | 1.5 |
| Interest expenses | 1.6 | 2.0 | 1.9 | 1.8 | 1.8 | 2.0 |
| Investment income | -0.6 | -0.9 | 0.1 | 0.0 | 0.0 | 0.0 |
| Financial result | -2.2 | -2.9 | -0.7 | 0.0 | -0.5 | -0.5 |
| Recurring pretax income from continuing operations | 25.2 | -30.3 | -9.1 | -10.5 | -2.3 | 7.5 |
| Extraordinary income/loss | -6.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Earnings before taxes | 19.0 | -30.3 | -9.1 | -10.5 | -2.3 | 7.5 |
| Income tax expense | 7.0 | 2.1 | 3.3 | 1.0 | 0.0 | 2.2 |
| Net income from continuing operations | 12.0 | -32.4 | -12.4 | -11.5 | -2.3 | 5.2 |
| Income from discontinued operations (net of tax) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income | 12.0 | -32.4 | -12.4 | -11.5 | -2.3 | 5.2 |
| Minority interest | 0.0 12.0 | 0.0 -32.4 | -0.2 -12.2 | -0.2 -11.3 | -0.2 -2.2 | -0.2 5.4 |
| Net profit (reported) Average number of shares | 21.7 | -32.4 21.5 | 20.1 | 20.1 | 20.1 | 20.1 |
| EPS reported | 0.55 | -1.51 | -0.61 | -0.56 | -0.11 | 0.27 |
| LF 3 Teported | 0.55 | -1.51 | -0.01 | -0.50 | -0.11 | 0.21 |
| Profit and loss (common size) | | 2022 | 2023 | 2024- | 2025e | 0000- |
| Front and 1035 (Common Size) | 2021 | 2022 | 2023 | 2024e | 20256 | 2026e |
| Sales | 2021 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| | 100.0% 50.9% | | 100.0% 50.3% | | 100.0% 48.7% | |
| Sales Cost of sales | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Sales Cost of sales Gross profit | 100.0% 50.9% 49.1% 29.9% | 100.0% 52.9% 47.1% 31.3% | 100.0% 50.3% 49.7% 31.7% | 100.0% 49.5% 50.5% 32.4% | 100.0% 48.7% 51.3% 32.0% | 100.0% 48.4% 51.6% 31.5% |
| Sales Cost of sales Gross profit Sales and marketing General and administration | 100.0% 50.9% 49.1% 29.9% 15.2% | 100.0% 52.9% 47.1% 31.3% 21.6% | 100.0% 50.3% 49.7% 31.7% 19.9% | 100.0% 49.5% 50.5% 32.4% 19.9% | 100.0% 48.7% 51.3% 32.0% 19.1% | 100.0% 48.4% 51.6% 31.5% 18.1% |
| Sales Cost of sales Gross profit Sales and marketing General and administration | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% | 100.0% 52.9% 47.1% 31.3% | 100.0% 50.3% 49.7% 31.7% | 100.0% 49.5% 50.5% 32.4% | 100.0% 48.7% 51.3% 32.0% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% |
| Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% 1.1% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 0.6% |
| Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 0.7% | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% 1.2% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 0.6% 1.0% |
| Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 0.7% | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% 1.1% 1.7% 2.6% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% 1.2% 3.5% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 0.6% 1.0% 5.0% |
| Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% 1.1% 1.7% 2.6% 2.0% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% 1.2% 3.5% 1.4% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 0.6% 1.0% 5.0% |
| Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 2.7% 1.5% 4.2% | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% 1.1% 1.7% 2.6% 2.0% 4.5% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% 1.2% 3.5% 1.4% 4.9% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 0.6% 1.0% 5.0% 6.4% |
| Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% 1.1% 1.7% 2.6% 2.0% 4.5% 3.3% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% 1.2% 3.5% 1.4% 4.9% 2.4% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 0.6% 1.0% 5.0% 6.4% 1.9% |
| Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% 1.1% 1.7% 2.6% 2.0% 4.5% 3.3% 0.0% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% 1.2% 3.5% 1.4% 4.9% 2.4% 0.0% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 0.6% 1.0% 5.0% 1.4% 6.4% 1.9% 0.0% |
| Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% 1.1% 1.7% 2.6% 2.0% 4.5% 3.3% 0.0% 1.6% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% 1.2% 3.5% 1.4% 4.9% 2.4% 0.0% 1.6% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 0.6% 1.0% 5.0% 1.4% 6.4% 1.9% 0.0% 1.5% |
| Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.7% | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% 1.1% 1.7% 2.6% 2.0% 4.5% 3.3% 0.0% 1.6% 0.0% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% 1.2% 3.5% 1.4% 4.9% 2.4% 0.0% 1.6% 0.0% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 0.6% 1.0% 5.0% 1.4% 6.4% 1.9% 0.0% 1.5% 0.0% |
| Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% -2.0% | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% 1.1% 1.7% 2.6% 2.0% 4.5% 3.3% 0.0% 1.6% 0.0% -2.4% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% 1.2% 3.5% 1.4% 4.9% 2.4% 0.0% 1.6% 0.0% -0.4% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 0.6% 1.0% 5.0% 1.4% 6.4% 1.9% 0.0% 1.5% 0.0% 1.6% |
| Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0% | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% -2.0% 0.3% | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% 1.1% 1.7% 2.6% 2.0% 4.5% 3.3% 0.0% 1.6% 0.0% -2.4% 0.4% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% 1.2% 3.5% 1.4% 4.9% 2.4% 0.0% 1.6% 0.0% -0.4% 0.3% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 0.6% 1.0% 5.0% 1.4% 6.4% 1.9% 0.0% 1.5% 0.0% 1.6% 0.3% |
| Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0% | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% 0.5% | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% -2.0% 0.3% 0.4% | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% 1.1% 1.7% 2.6% 2.0% 4.5% 3.3% 0.0% 1.6% 0.0% -2.4% 0.4% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% 1.2% 3.5% 1.4% 4.9% 2.4% 0.0% 1.6% 0.0% -0.4% 0.3% 0.4% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 0.6% 1.0% 5.0% 1.4% 6.4% 0.0% 1.5% 0.0% 1.6% 0.3% 0.4% |
| Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0% 0.3% -0.1% | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% 0.5% -0.2% | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% 0.3% 0.4% 0.0% | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% 1.1% 1.7% 2.6% 2.0% 4.5% 3.3% 0.0% 1.6% 0.0% -2.4% 0.4% 0.4% 0.0% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% 1.2% 3.5% 1.4% 4.9% 2.4% 0.0% 1.6% 0.0% -0.4% 0.3% 0.4% 0.0% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 1.0% 5.0% 1.4% 6.4% 0.0% 1.5% 0.0% 1.6% 0.3% 0.4% 0.0% |
| Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0% 0.3% -0.1% neg. | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% 0.5% -0.2% neg. | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% 0.3% 0.4% 0.0% neg. | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% 1.1% 1.7% 2.6% 2.0% 4.5% 3.3% 0.0% 1.6% 0.0% -2.4% 0.4% 0.4% 0.0% 0.0% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% 1.2% 3.5% 1.4% 4.9% 2.4% 0.0% 1.6% 0.0% -0.4% 0.3% 0.4% 0.0% neg. | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 1.0% 5.0% 1.4% 6.4% 0.0% 1.5% 0.0% 1.6% 0.3% 0.4% 0.0% neg. |
| Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0% 0.3% -0.1% neg. 4.8% | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% 0.5% -0.2% neg7.0% | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% 0.3% 0.4% 0.0% neg2.1% | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% 1.1% 1.7% 2.6% 2.0% 4.5% 3.3% 0.0% 1.6% 0.0% -2.4% 0.4% 0.0% 0.0% -2.4% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% 1.2% 3.5% 1.4% 4.9% 2.4% 0.0% 1.6% 0.0% -0.4% 0.3% 0.4% 0.0% neg0.5% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 1.0% 5.0% 1.4% 6.4% 0.0% 1.5% 0.0% 1.6% 0.3% 0.4% 0.0% neg. 1.5% |
| Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0% 0.3% -0.1% neg. 4.8% -1.2% | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% 0.5% -0.2% neg7.0% 0.0% | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% 0.3% 0.4% 0.0% neg2.1% 0.0% | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% 1.1% 1.7% 2.6% 2.0% 4.5% 3.3% 0.0% 1.6% 0.0% -2.4% 0.4% 0.0% 0.0% -2.4% 0.0% 0.0% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% 1.2% 3.5% 1.4% 4.9% 2.4% 0.0% 1.6% 0.0% -0.4% 0.3% 0.4% 0.0% neg0.5% 0.0% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 1.0% 5.0% 1.4% 6.4% 0.0% 1.5% 0.0% 1.6% 0.3% 0.4% 0.0% neg. 1.5% 0.0% |
| Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0% 0.3% -0.1% neg. 4.8% -1.2% 3.6% | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% 0.5% -0.2% neg7.0% | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% -2.0% 0.3% 0.4% 0.0% neg2.1% | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% 1.1% 1.7% 2.6% 2.0% 4.5% 3.3% 0.0% 1.6% 0.0% -2.4% 0.4% 0.0% 0.0% -2.4% 0.0% -2.4% 0.0% -2.4% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% 1.2% 3.5% 1.4% 4.9% 2.4% 0.0% 1.6% 0.0% -0.4% 0.3% 0.4% 0.0% neg0.5% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 1.0% 5.0% 1.4% 6.4% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% |
| Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0% 0.3% -0.1% neg. 4.8% -1.2% 3.6% 36.8% | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% 0.5% -0.2% neg7.0% 0.0% -7.0% | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% -2.0% 0.3% 0.4% 0.0% neg2.1% -36.3% | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% 1.1% 1.7% 2.6% 2.0% 4.5% 3.3% 0.0% 1.6% 0.0% -2.4% 0.4% 0.0% -2.4% 0.0% -2.4% 0.0% -2.4% 0.0% -2.4% -9.4% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% 1.2% 3.5% 1.4% 4.9% 2.4% 0.0% 1.6% 0.0% -0.4% 0.3% 0.4% 0.0% neg0.5% 0.0% -0.5% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 1.0% 5.0% 1.4% 6.4% 0.0% 1.5% 0.0% 1.6% 0.3% 0.4% 0.0% neg. 1.5% 0.0% 1.5% 30.0% |
| Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income from continuing operations | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0% 0.3% -0.1% neg. 4.8% -1.2% 3.6% 36.8% 2.3% | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% 0.5% -0.2% neg7.0% 0.0% -7.0% -6.9% -7.5% | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% -2.0% 0.3% 0.4% 0.0% neg2.1% -36.3% -2.9% | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% 1.1% 1.7% 2.6% 2.0% 4.5% 3.3% 0.0% 1.6% 0.0% -2.4% 0.4% 0.0% -2.4% 0.0% -2.4% -9.4% -9.4% -2.6% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% 1.2% 3.5% 1.4% 4.9% 2.4% 0.0% 1.6% 0.0% -0.4% 0.3% 0.4% 0.0% neg0.5% 0.0% -0.5% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 1.0% 5.0% 1.4% 6.4% 0.0% 1.5% 0.0% 1.6% 0.3% 0.4% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 1.0% |
| Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income Income Income from continuing operations Net income | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0% 0.3% -0.1% neg. 4.8% -1.2% 3.6% 36.8% 2.3% | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% 0.5% -0.2% neg7.0% -6.9% -7.5% | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% -2.0% 0.3% 0.4% 0.0% neg2.1% -36.3% -2.9% -2.9% | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% 1.1% 1.7% 2.6% 2.0% 4.5% 3.3% 0.0% 1.6% 0.0% -2.4% 0.4% 0.0% -2.4% 0.0% -2.4% -2.6% -2.6% -2.6% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% 1.2% 3.5% 1.4% 4.9% 2.4% 0.0% 1.6% 0.0% -0.4% 0.3% 0.4% 0.0% neg0.5% 0.0% -0.5% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 1.0% 5.0% 1.4% 6.4% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 1.0% 1.0% 1.5% |
| Sales Cost of sales Gross profit Sales and marketing General and administration Research and development Other operating income Other operating expenses EBITDA Unusual or infrequent items Adj. EBITDA Depreciation Amortisation of goodwill Amortisation of intangible assets Impairment charges EBIT (inc revaluation net) Interest income Interest expenses Investment income Financial result Recurring pretax income from continuing operations Extraordinary income/loss Earnings before taxes Tax rate Net income from continuing operations | 100.0% 50.9% 49.1% 29.9% 15.2% 0.0% 0.7% 7.7% 1.2% 7.7% 1.8% 0.0% 0.7% 0.0% 5.2% 0.0% 0.3% -0.1% neg. 4.8% -1.2% 3.6% 36.8% 2.3% | 100.0% 52.9% 47.1% 31.3% 21.6% 0.0% 0.6% 1.2% -2.2% 0.0% -1.0% 2.8% 0.0% 1.3% 0.0% -6.4% 0.0% 0.5% -0.2% neg7.0% 0.0% -7.0% -6.9% -7.5% | 100.0% 50.3% 49.7% 31.7% 19.9% 0.0% 1.4% 1.4% 2.7% 1.5% 4.2% 3.1% 0.0% 1.5% 0.0% -2.0% 0.3% 0.4% 0.0% neg2.1% -36.3% -2.9% | 100.0% 49.5% 50.5% 32.4% 19.9% 0.0% 1.1% 1.7% 2.6% 2.0% 4.5% 3.3% 0.0% 1.6% 0.0% -2.4% 0.4% 0.0% -2.4% 0.0% -2.4% -9.4% -9.4% -2.6% | 100.0% 48.7% 51.3% 32.0% 19.1% 0.0% 0.6% 1.2% 3.5% 1.4% 4.9% 2.4% 0.0% 1.6% 0.0% -0.4% 0.3% 0.4% 0.0% neg0.5% 0.0% -0.5% | 100.0% 48.4% 51.6% 31.5% 18.1% 0.0% 1.0% 5.0% 1.4% 6.4% 0.0% 1.5% 0.0% 1.6% 0.3% 0.4% 0.0% 1.5% 0.0% 1.5% 0.0% 1.5% 1.0% |

Source: Company data, NuWays

Update - 29.01.2025



| Balance sheet (EUR m) | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
|--|-------------------------------|-------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| Intangible assets | 18.9 | 23.3 | 19.3 | 19.5 | 19.5 | 19.5 |
| Property, plant and equipment | 55.5 | 53.2 | 44.6 | 34.6 | 34.6 | 34.6 |
| Financial assets | 0.0 | 2.3 | 1.6 | 1.6 | 1.6 | 1.6 |
| FIXED ASSETS | 74.4 | 78.8 | 65.5 | 55.7 | 55.7 | 55.7 |
| Inventories | 54.9 | 45.2 | 28.1 | 24.0 | 24.8 | 25.8 |
| Accounts receivable | 11.5 | 12.6 | 12.1 | 12.3 | 13.7 | 14.3 |
| Other assets and short-term financial assets | 18.9 | 22.2 | 7.6 | 5.0 | 9.2 | 9.5 |
| Liquid assets | 97.4 | 62.3 | 81.5 | 74.6 | 75.0 | 83.2 |
| Deferred taxes | 8.2 | 3.6 | 1.5 | 1.5 | 1.5 | 1.5 |
| Deferred charges and prepaid expenses | 12.1 | 3.6 | 7.1 | 7.1 | 7.1 | 7.1 |
| CURRENT ASSETS | 203.0 | 149.5 | 137.9 | 124.5 | 131.3 | 141.5 |
| TOTAL ASSETS | 277.4 | 228.3 | 203.4 | 180.2 | 187.0 | 197.2 |
| SHAREHOLDERS EQUITY | 119.3 | 90.0 | 75.0 | 53.6 | 65.2 | 79.5 |
| MINORITY INTEREST | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term liabilities to banks | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Bonds (long-term) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| other interest-bearing liabilities | 10.3 | 6.1 | 6.0 | 6.0 | 6.0 | 6.0 |
| Provisions for pensions and similar obligations | 1.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 |
| Other provisions and accrued liabilities | 0.7 | 0.6 | 1.5 | 1.5 | 1.5 | 1.5 |
| NON-CURRENT LIABILITIES | 12.1 | 8.8 | 9.6 | 9.6 | 9.6 | 9.6 |
| Short-term liabilities to banks | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Accounts payable | 81.6 | 57.9 | 61.8 | 66.0 | 68.2 | 71.1 |
| Advance payments received on orders | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Accrued taxes | 1.0 | 1.7 | 0.9 | 0.9 | 0.9 | 0.9 |
| Other liabilities (incl. from lease and rental contracts) | 58.3 | 67.6 | 53.0 | 47.0 | 40.0 | 33.0 |
| Deferred taxes | 5.1 | 2.3 | 3.1 | 3.1 | 3.1 | 3.1 |
| Deferred income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| CURRENT LIABILITIES TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | 146.0 277.4 | 129.5 228.3 | 118.8 203.4 | 117.0 180.2 | 112.2 187.0 | 108.1 197.2 |
| Palanas shoot (samman siza) | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
| Balance sheet (common size) Intangible assets | 6.8% | 10.2% | 9.5% | 10.8% | 10.4% | 9.9% |
| Property, plant and equipment | 20.0% | 23.3% | 21.9% | 19.2% | 18.5% | 17.5% |
| Financial assets | 0.0% | 1.0% | 0.8% | 0.9% | 0.9% | 0.8% |
| FIXED ASSETS | 26.8% | 34.5% | 32.2% | 30.9% | 29.8% | 28.2% |
| Inventories | 19.8% | 19.8% | 13.8% | 13.3% | 13.3% | 13.1% |
| Accounts receivable | 4.1% | 5.5% | 5.9% | 6.8% | 7.3% | 7.3% |
| Other assets and short-term financial assets | 6.8% | 9.7% | 3.7% | 2.8% | 4.9% | 4.8% |
| Liquid assets | 35.1% | 27.3% | 40.1% | 41.4% | 40.1% | 42.2% |
| Deferred taxes | 3.0% | 1.6% | 0.7% | 0.8% | 0.8% | 0.8% |
| Deferred charges and prepaid expenses | 4.4% | 1.6% | 3.5% | 3.9% | 3.8% | 3.6% |
| CURRENT ASSETS | 73.2% | 65.5% | 67.8% | 69.1% | 70.2% | 71.8% |
| TOTAL ASSETS | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| SHAREHOLDERS EQUITY | 43.0% | 39.4% | 36.9% | 29.8% | 34.9% | 40.3% |
| MINORITY INTEREST | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Long-term liabilities to banks | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Bonds (long-term) | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| other interest-bearing liabilities | 3.7% | 2.7% | 2.9% | 3.3% | 3.2% | 3.0% |
| Provisions for pensions and similar obligations | 0.4% | 0.9% | 1.0% | 1.2% | 1.1% | 1.1% |
| Other provisions and accrued liabilities | 0.3% | 0.3% | 0.7% | 0.8% | 0.8% | 0.8% |
| NON-CURRENT LIABILITIES | 4.4% | 3.9% | 4.7% | 5.3% | 5.1% | 4.9% |
| Short-term liabilities to banks | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Accounts payable | 29.4% | 25.4% | 30.4% | 36.6% | 36.5% | 36.0% |
| | Λ Λ0/ | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Advance payments received on orders | 0.0% | | | | | |
| Accrued taxes | 0.4% | 0.7% | 0.4% | 0.5% | 0.5% | 0.5% |
| Accrued taxes Other liabilities (incl. from lease and rental contracts) | 0.4% 21.0% | 0.7% 29.6% | 26.1% | 26.1% | 21.4% | 16.7% |
| Accrued taxes Other liabilities (incl. from lease and rental contracts) Deferred taxes | 0.4% 21.0% 1.8% | 0.7% 29.6% 1.0% | 26.1% 1.5% | 26.1% 1.7% | 21.4% 1.7% | 16.7% 1.6% |
| Accrued taxes Other liabilities (incl. from lease and rental contracts) Deferred taxes Deferred income | 0.4% 21.0% 1.8% 0.0% | 0.7% 29.6% 1.0% 0.0% | 26.1% 1.5% 0.0% | 26.1% 1.7% 0.0% | 21.4% 1.7% 0.0% | 16.7% 1.6% 0.0% |
| Accrued taxes Other liabilities (incl. from lease and rental contracts) Deferred taxes | 0.4% 21.0% 1.8% | 0.7% 29.6% 1.0% | 26.1% 1.5% | 26.1% 1.7% | 21.4% 1.7% | 16.7% 1.6% |

Source: Company data, NuWays

Update - 29.01.2025

Cash flow statement (EUR m)



2025e

2026e

| | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
|--|---|--|--|---|--|---|
| Net profit/loss | 12.0 | -32.4 | -12.4 | -11.5 | -2.3 | 5.2 |
| Depreciation of fixed assets (incl. leases) | 9.2 | 12.2 | 13.2 | 14.6 | 10.8 | 9.4 |
| Amortisation of goodwill & intangible assets | 3.8 | 5.8 | 6.6 | 7.3 | 7.2 | 7.6 |
| Other costs affecting income / expenses | -27.4 | 21.0 | 4.4 | 2.6 | 0.0 | 0.0 |
| Cash flow from operating activities | 6.8 | -18.6 | 29.0 | 11.4 | 9.0 | 16.8 |
| Increase/decrease in inventory | -24.7 | 9.7 | 17.1 | 4.1 | -0.8 | -1.0 |
| Increase/decrease in accounts receivable | 5.9 | -1.1 | 0.5 | -0.2 | -1.4 | -0.6 |
| Increase/decrease in accounts payable | 39.9 | -23.7 | 3.9 | 4.2 | 2.2 | 2.9 |
| | | | | | | |
| Increase/decrease in other working capital positions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Increase/decrease in working capital | 21.1 | -15.1 | 21.5 | 8.1 | -0.0 | 1.2 |
| Cash flow from operating activities | 18.7 | -7.5 | 33.3 | 21.1 | 15.6 | 23.5 |
| CAPEX | 14.9 | 13.9 | 5.4 | 12.1 | 8.2 | 8.3 |
| Payments for acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Financial investments | 1.1 | 2.5 | 1.6 | 0.0 | 0.0 | 0.0 |
| Income from asset disposals | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cash flow from investing activities | -16.0 | -11.4 | -3.8 | -12.1 | -8.2 | -8.3 |
| Cash flow before financing | 2.7 | -23.9 | 26.3 | 9.0 | 7.4 | 15.2 |
| Increase/decrease in debt position | 0.0 | -4.2 | -0.1 | 0.0 | 0.0 | 0.0 |
| Purchase of own shares | 0.0 | -0.5 | -3.7 | 9.9 | 0.0 | 0.0 |
| Capital measures | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Dividends paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| | | | | | | |
| Others | -10.1 | 1.0 | -20.1 | -6.0 | -7.0 | -7.0 |
| Effects of exchange rate changes on cash | -0.5 | 0.2 | -0.1 | 0.0 | 0.0 | 0.0 |
| Cash flow from financing activities | -9.7 | -2.7 | -23.9 | -15.9 | -7.0 | -7.0 |
| Increase/decrease in liquid assets | -7.5 | -26.4 | 9.7 | -6.9 | 0.4 | 8.2 |
| Liquid assets at end of period | 97.4 | 76.0 | 81.5 | 74.6 | 75.0 | 83.2 |
| | | | | | 2005 | |
| Key ratios (EUR m) | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
| P&L growth analysis | | | | | | |
| Sales growth | 20.7% | -17.6% | -0.5% | 3.3% | 3.4% | 9.7% |
| EBITDA growth | -19.2% | -123.3% | -221.3% | -0.0% | 41.3% | 55.0% |
| EBIT growth | -30.4% | -200.0% | -69.3% | 25.0% | -82.0% | -522.3% |
| EPS growth | -53.2% | -373.1% | -59.7% | -7.5% | -80.9% | -350.6% |
| Efficiency | | | | | | |
| Sales per employee | 290.1 | 253.4 | 218.4 | 265.0 | 278.8 | 255.8 |
| EBITDA per employee | 22.4 | -5.5 | 5.8 | 6.8 | 9.8 | 12.7 |
| No. employees (average) | 1,801 | 1,700 | 1,963 | 1,672 | 1,642 | 1,963 |
| Balance sheet analysis | ., | ., | 1,222 | ., | ., | 1,000 |
| Avg. working capital / sales | -0.9% | -1.8% | -2.5% | -5.8% | -6.5% | -6.0% |
| Inventory turnover (sales/inventory) | 4.8 | 5.0 | 7.7 | 9.1 | 9.0 | 9.4 |
| Accounts receivable turnover | 8.0 | 10.7 | 10.3 | 10.3 | 10.3 | 10.3 |
| | 112.1 | 92.7 | 10.5 | 10.3 | 111.6 | 10.3 |
| Accounts payable turnover | 112.1 | 92.1 | 104.0 | 109.9 | 111.0 | 100.7 |
| Cash flow analysis | 0.0 | 04.4 | 00.5 | | - 4 | 45.0 |
| Free cash flow | 3.8 | -21.4 | 29.5 | 9.0 | 7.4 | 15.2 |
| Free cash flow/sales | n 7% | -5.0% | 6 O 0/ | 2 00/- | 1 60/ | 3.0% |
| | 0.7% | | 6.9% | 2.0% | 1.6% | |
| FCF / net profit | 31.7% | 66.0% | neg. | neg. | neg. | 290.4% |
| FCF / net profit Capex / sales | | | | | | |
| | 31.7% | 66.0% | neg. | neg. | neg. | 290.4% |
| Capex / sales | 31.7% | 66.0% | neg. | neg. | neg. | 290.4% |
| Capex / sales Solvency Net debt | 31.7% 3.1% -87.1 | 66.0% 3.8% -56.2 | neg. 1.6% -82.0 | neg. 2.7% -68.6 | neg. 1.8% -69.0 | 290.4% 1.6% -77.2 |
| Capex / sales Solvency Net debt Net Debt/EBITDA | 31.7% 3.1% -87.1 0.0 | 66.0% 3.8% -56.2 0.0 | neg. 1.6% -82.0 0.0 | neg. 2.7% -68.6 0.0 | neg. 1.8% -69.0 0.0 | 290.4% 1.6% -77.2 0.0 |
| Capex / sales Solvency Net debt Net Debt/EBITDA Dividend payout ratio | 31.7% 3.1% -87.1 0.0 0.0% | 66.0% 3.8% -56.2 0.0 0.0% | neg. 1.6% -82.0 0.0 0.0% | neg. 2.7% -68.6 0.0 0.0% | neg. 1.8% -69.0 0.0 0.0% | 290.4% 1.6% -77.2 0.0 0.0% |
| Capex / sales Solvency Net debt Net Debt/EBITDA Dividend payout ratio Interest paid / avg. debt | 31.7% 3.1% -87.1 0.0 | 66.0% 3.8% -56.2 0.0 | neg. 1.6% -82.0 0.0 | neg. 2.7% -68.6 0.0 | neg. 1.8% -69.0 0.0 | 290.4% 1.6% -77.2 0.0 |
| Capex / sales Solvency Net debt Net Debt/EBITDA Dividend payout ratio Interest paid / avg. debt Returns | 31.7% 3.1% -87.1 0.0 0.0% 21.6% | 66.0% 3.8% -56.2 0.0 0.0% 24.4% | neg. 1.6% -82.0 0.0 0.0% 31.4% | neg. 2.7% -68.6 0.0 0.0% 29.5% | neg. 1.8% -69.0 0.0 0.0% 30.5% | 290.4% 1.6% -77.2 0.0 0.0% 33.5% |
| Capex / sales Solvency Net debt Net Debt/EBITDA Dividend payout ratio Interest paid / avg. debt Returns ROCE | 31.7% 3.1% -87.1 0.0 0.0% 21.6% | 66.0% 3.8% -56.2 0.0 0.0% 24.4% | neg. 1.6% -82.0 0.0 0.0% 31.4% | neg. 2.7% -68.6 0.0 0.0% 29.5% | neg. 1.8% -69.0 0.0 0.0% 30.5% | 290.4% 1.6% -77.2 0.0 0.0% 33.5% |
| Capex / sales Solvency Net debt Net Debt/EBITDA Dividend payout ratio Interest paid / avg. debt Returns ROCE ROE | 31.7% 3.1% -87.1 0.0 0.0% 21.6% 22.2% 10.1% | 66.0% 3.8% -56.2 0.0 0.0% 24.4% -23.5% -36.0% | neg. 1.6% -82.0 0.0 0.0% 31.4% -9.0% -16.3% | neg. 2.7% -68.6 0.0 0.0% 29.5% -14.0% -21.1% | neg. 1.8% -69.0 0.0 0.0% 30.5% -2.7% -3.3% | 290.4% 1.6% -77.2 0.0 0.0% 33.5% 9.6% 6.8% |
| Capex / sales Solvency Net debt Net Debt/EBITDA Dividend payout ratio Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield | 31.7% 3.1% -87.1 0.0 0.0% 21.6% 22.2% 10.1% 3.0% | 66.0% 3.8% -56.2 0.0 0.0% 24.4% -23.5% -36.0% -13.6% | neg. 1.6% -82.0 0.0 0.0% 31.4% -9.0% -16.3% 4.3% | neg. 2.7% -68.6 0.0 0.0% 29.5% -14.0% -21.1% 1.0% | neg. 1.8% -69.0 0.0 0.0% 30.5% -2.7% -3.3% 10.7% | 290.4% 1.6% -77.2 0.0 0.0% 33.5% 9.6% 6.8% 19.8% |
| Capex / sales Solvency Net debt Net Debt/EBITDA Dividend payout ratio Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield | 31.7% 3.1% -87.1 0.0 0.0% 21.6% 22.2% 10.1% 3.0% 0.0% | -56.2 0.0 0.0% 24.4% -23.5% -36.0% -13.6% 0.0% | neg. 1.6% -82.0 0.0 0.0% 31.4% -9.0% -16.3% 4.3% 0.0% | neg. 2.7% -68.6 0.0 0.0% 29.5% -14.0% -21.1% 1.0% 0.0% | neg. 1.8% -69.0 0.0 0.0% 30.5% -2.7% -3.3% 10.7% 0.0% | 290.4% 1.6% -77.2 0.0 0.0% 33.5% 9.6% 6.8% 19.8% 0.0% |
| Capex / sales Solvency Net debt Net Debt/EBITDA Dividend payout ratio Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS | 31.7% 3.1% -87.1 0.0 0.0% 21.6% 22.2% 10.1% 3.0% 0.0% | -56.2 0.0 0.0% 24.4% -23.5% -36.0% -13.6% 0.0% | neg. 1.6% -82.0 0.0 0.0% 31.4% -9.0% -16.3% 4.3% 0.0% 0.0 | neg. 2.7% -68.6 0.0 0.0% 29.5% -14.0% -21.1% 1.0% 0.0% 0.0 | neg. 1.8% -69.0 0.0 0.0% 30.5% -2.7% -3.3% 10.7% 0.0% 0.0 | 290.4% 1.6% -77.2 0.0 0.0% 33.5% 9.6% 6.8% 19.8% 0.0% 0.0 |
| Capex / sales Solvency Net debt Net Debt/EBITDA Dividend payout ratio Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS EPS reported | 31.7% 3.1% -87.1 0.0 0.0% 21.6% 22.2% 10.1% 3.0% 0.0% 0.055 | -56.2 0.0 0.0% 24.4% -23.5% -36.0% -13.6% 0.0% 0.0 -1.51 | neg. 1.6% -82.0 0.0 0.0% 31.4% -9.0% -16.3% 4.3% 0.0% 0.0 -0.61 | neg. 2.7% -68.6 0.0 0.0% 29.5% -14.0% -21.1% 1.0% 0.0% 0.0 -0.56 | neg. 1.8% -69.0 0.0 0.0% 30.5% -2.7% -3.3% 10.7% 0.0% 0.0 | 290.4% 1.6% -77.2 0.0 0.0% 33.5% 9.6% 6.8% 19.8% 0.0% 0.0 0.27 |
| Capex / sales Solvency Net debt Net Debt/EBITDA Dividend payout ratio Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS | 31.7% 3.1% -87.1 0.0 0.0% 21.6% 22.2% 10.1% 3.0% 0.0% | -56.2 0.0 0.0% 24.4% -23.5% -36.0% -13.6% 0.0% | neg. 1.6% -82.0 0.0 0.0% 31.4% -9.0% -16.3% 4.3% 0.0% 0.0 | neg. 2.7% -68.6 0.0 0.0% 29.5% -14.0% -21.1% 1.0% 0.0% 0.0 | neg. 1.8% -69.0 0.0 0.0% 30.5% -2.7% -3.3% 10.7% 0.0% 0.0 | 290.4% 1.6% -77.2 0.0 0.0% 33.5% 9.6% 6.8% 19.8% 0.0% 0.0 |
| Capex / sales Solvency Net debt Net Debt/EBITDA Dividend payout ratio Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS EPS reported | 31.7% 3.1% -87.1 0.0 0.0% 21.6% 22.2% 10.1% 3.0% 0.0% 0.055 | -56.2 0.0 0.0% 24.4% -23.5% -36.0% -13.6% 0.0% 0.0 -1.51 | neg. 1.6% -82.0 0.0 0.0% 31.4% -9.0% -16.3% 4.3% 0.0% 0.0 -0.61 | neg. 2.7% -68.6 0.0 0.0% 29.5% -14.0% -21.1% 1.0% 0.0% 0.0 -0.56 | neg. 1.8% -69.0 0.0 0.0% 30.5% -2.7% -3.3% 10.7% 0.0% 0.0 | 290.4% 1.6% -77.2 0.0 0.0% 33.5% 9.6% 6.8% 19.8% 0.0% 0.0 0.27 |
| Capex / sales Solvency Net debt Net Debt/EBITDA Dividend payout ratio Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS EPS reported Average number of shares | 31.7% 3.1% -87.1 0.0 0.0% 21.6% 22.2% 10.1% 3.0% 0.0% 0.055 | -56.2 0.0 0.0% 24.4% -23.5% -36.0% -13.6% 0.0% 0.0 -1.51 | neg. 1.6% -82.0 0.0 0.0% 31.4% -9.0% -16.3% 4.3% 0.0% 0.0 -0.61 | neg. 2.7% -68.6 0.0 0.0% 29.5% -14.0% -21.1% 1.0% 0.0% 0.0 -0.56 | neg. 1.8% -69.0 0.0 0.0% 30.5% -2.7% -3.3% 10.7% 0.0% 0.0 | 290.4% 1.6% -77.2 0.0 0.0% 33.5% 9.6% 6.8% 19.8% 0.0% 0.0 0.27 |
| Capex / sales Solvency Net debt Net Debt/EBITDA Dividend payout ratio Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS EPS reported Average number of shares Valuation ratios | 31.7% 3.1% -87.1 0.0 0.0% 21.6% 22.2% 10.1% 3.0% 0.0% 0.0 0.55 21.7 | 66.0% 3.8% -56.2 0.0 0.0% 24.4% -23.5% -36.0% -13.6% 0.0% 0.0 -1.51 21.5 | neg. 1.6% -82.0 0.0 0.0% 31.4% -9.0% -16.3% 4.3% 0.0% 0.0 -0.61 20.1 | neg. 2.7% -68.6 0.0 0.0% 29.5% -14.0% -21.1% 1.0% 0.0% 0.0 -0.56 20.1 | neg. 1.8% -69.0 0.0 0.0% 30.5% -2.7% -3.3% 10.7% 0.0% 0.0 -0.11 20.1 | 290.4% 1.6% -77.2 0.0 0.0% 33.5% 9.6% 6.8% 19.8% 0.0% 0.0 0.27 20.1 |
| Capex / sales Solvency Net debt Net Debt/EBITDA Dividend payout ratio Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS EPS reported Average number of shares Valuation ratios P/BV EV/sales | 31.7% 3.1% -87.1 0.0 0.0% 21.6% 22.2% 10.1% 3.0% 0.0% 0.0 0.55 21.7 | 66.0% 3.8% -56.2 0.0 0.0% 24.4% -23.5% -36.0% -13.6% 0.0% 0.0 -1.51 21.5 | neg. 1.6% -82.0 0.0 0.0% 31.4% -9.0% -16.3% 4.3% 0.0% 0.0 -0.61 20.1 | neg. 2.7% -68.6 0.0 0.0% 29.5% -14.0% -21.1% 1.0% 0.0% 0.0 -0.56 20.1 | neg. 1.8% -69.0 0.0 0.0% 30.5% -2.7% -3.3% 10.7% 0.0% 0.0 -0.11 20.1 | 290.4% 1.6% -77.2 0.0 0.0% 33.5% 9.6% 6.8% 19.8% 0.0% 0.0 0.27 20.1 |
| Capex / sales Solvency Net debt Net Debt/EBITDA Dividend payout ratio Interest paid / avg. debt Returns ROCE ROE Adjusted FCF yield Dividend yield DPS EPS reported Average number of shares Valuation ratios P/BV | 31.7% 3.1% -87.1 0.0 0.0% 21.6% 22.2% 10.1% 3.0% 0.0% 0.0 0.55 21.7 | 66.0% 3.8% -56.2 0.0 0.0% 24.4% -23.5% -36.0% -13.6% 0.0% 0.0 -1.51 21.5 | neg. 1.6% -82.0 0.0 0.0% 31.4% -9.0% -16.3% 4.3% 0.0% 0.0 -0.61 20.1 | neg. 2.7% -68.6 0.0 0.0% 29.5% -14.0% -21.1% 1.0% 0.0% 0.0 -0.56 20.1 | neg. 1.8% -69.0 0.0 0.0% 30.5% -2.7% -3.3% 10.7% 0.0% 0.0 -0.11 20.1 | 290.4% 1.6% -77.2 0.0 0.0% 33.5% 9.6% 6.8% 19.8% 0.0% 0.0 0.27 20.1 |

2021

2022

2023

2024e

Update - 29.01.2025



Disclosures

Disclosures regarding research publications of NuWays AG pursuant to section 85 of the German Securities Trading Act (WpHG)

Indication of conflict of interest

It is essential that any research recommendation is fairly presented and discloses interests of indicates relevant conflicts of interest. Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analysed company. A conflict of interest is presumed to exist in particular if NuWays AG

- (1) or any other person belonging to the same group with it was part of a consortium within the past twelve months that issued the financial instruments of the analysed company by way of a public offer.
- (2) or any other person belonging to the same group with it has entered into an agreement on the production of the research report with the analysed company.
- (3) or any other person belonging to the same group with it has been party to an agreement on the provision of investment banking services with the analysed company or have received services or a promise of services under the term of such an agreement within the past twelve month.
- (4) The analysed company holds 5% or more of the share capital of NuWays AG.
- (5) holds (a) a net short position or (b) a net long position of 0.5% of the outstanding share capital of the analysed company.
- (6) or any other person belonging to the same group with it is a market maker or liquidity provider in the financial instruments of the issuer.
- (7) or the analyst has any other significant financial interests relating to the analysed company such as, for example, exercising mandates in the interest of the analysed company.
- (8) The research report has been made available to the analysed company prior to its publication. Thereafter, only factual changes have been made to the report.

Conflicts of interest that existed at the time when this research report was published:

| Company | Disclosures |
|-------------------|-------------|
| Westwing Group SE | 2 |

| Historical target price and | rating changes for Westwin | g Group SE | | | |
|-----------------------------|----------------------------|-----------------|--------|--------------|----------|
| Company | Date | Analyst | Rating | Target Price | Close |
| Westwing Group SE | 05.12.2024 | Schüssler, Mark | Buy | EUR 17.00 | EUR 7.98 |
| - ' | 09.08.2024 | Schüssler, Mark | Buy | EUR 17.50 | EUR 7.64 |
| | 01.04.2024 | Schüssler, Mark | Buy | EUR 18.00 | EUR 7.90 |
| | 28.03.2024 | Schüssler, Mark | Buy | EUR 17.00 | EUR 7.69 |

Update - 29.01.2025



1. General Information/Liabilities

This research report has been produced for the information purposes of institutional investors only, and is not in any way a personal recommendation, offer or solicitation to buy or sell the financial instruments mentioned herein. The document is confidential and is made available by NuWays AG exclusively to selected recipients in the European Union (EU) or, in individual cases, also in other countries. It is not allowed to pass the research report on to persons other than the intended recipient without the permission of NuWays AG. Reproduction of this document, in whole or in part, is not permitted without prior permission NuWays AG. All rights reserved.

Under no circumstances shall NuWays AG, any of its employees involved in the preparation, have any liability for possible errors or incompleteness of the information included in this research report – neither in relation to indirect or direct nor consequential damages. Liability for damages arising either directly or as a consequence of the use of information, opinions and estimates is also excluded. Past performance of a financial instrument is not necessarily indicative of future performance.

2. Responsibilities

This research report was prepared by the research analyst named on the front page (the "Producer"). The Producer is solely responsible for the views and estimates expressed in this report. The report has been prepared independently. The content of the research report was not influenced by the issuer of the analysed financial instrument at any time. It may be possible that parts of the research report were handed out to the issuer for information purposes prior to the publication without any major amendments being made thereafter.

3. Organisational Requirements

NuWays AG took internal organisational and regulative precautions to avoid or accordingly disclose possible conflicts of interest in connection with the preparation and distribution of the research report. All members of NuWays AG involved in the preparation of the research report are subject to internal compliance regulations. No part of the Producer's compensation is directly or indirectly related to the preparation of this financial analysis. In case a research analyst or a closely related person is confronted with a conflict of interest, the research analyst is restricted from covering this company.

4. Information Concerning the Methods of Valuation/Update

The determination of the fair value per share, i.e. the price target, and the resultant rating is done on the basis of the adjusted free cash flow (adj. FCF) method and on the basis of the discounted cash flow – DCF model. Furthermore, a peer group comparison is made.

The adj. FCF method is based on the assumption that investors purchase assets only at a price (enterprise value) at which the operating cash flow return after taxes on this investment exceeds their opportunity costs in the form of a hurdle rate of 7.5%. The operating cash flow is calculated as EBITDA less maintenance capex and taxes.

Within the framework of the DCF approach, the future free cash flows are calculated initially on the basis of a fictitious capital structure of 100% equity, i.e. interest and repayments on debt capital are not factored in initially. The adjust-

ment towards the actual capital structure is done by discounting the calculated free cash flows with the weighted average cost of capital (WACC), which takes into account both the cost of equity capital and the cost of debt. After discounting, the calculated total enterprise value is reduced by the interest-bearing debt capital in order to arrive at the equity value.

NuWays AG uses the following three-step rating system for the analysed com-

Buy: Sustainable upside potential of more than 20% within 12 months

Sell: Sustainable downside potential of more than 20% within 12 months.

Hold: Upside/downside potential is limited. No immediate catalyst visible.

The decision on the choice of the financial instruments analysed in this document was solely made by NuWays AG. The opinions and estimates in this research report are subject to change without notice. It is within the discretion of NuWays AG whether and when it publishes an update to this research report, but in general updates are created on a regular basis, after 6 months at the latest. A sensitivity analysis is included and published in company's initial studies.

5. Major Sources of Information

Part of the information required for this research report was made available by the issuer of the financial instrument. Furthermore, this report is based on publicly available sources (such as, for example, Bloomberg, Reuters, VWD-Trader and the relevant daily press) believed to be reliable. NuWays AG has checked the information for plausibility but not for accuracy or completeness.

6. Competent Supervisory Authority

NuWays AG is an affiliated company of Hauck Aufhäuser Lampe Privatbank AG which is under supervision of the BaFin – German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), Graurheindorfer Straße 108, 53117 Bonn and Marie-Curie-Straße 24 – 28, 60439 Frankfurt a.M.

7. Specific Comments for Recipients Outside of Germany

This research report is subject to the law of the Federal Republic of Germany and the European Union (EU). The distribution of this information to other states in particular to the USA, Canada, Australia and Japan may be restricted or prohibited by the laws applicable within this state. If this communication is distributed in the United Kingdom it is solely directed at (i) investment professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO") or (ii) high net-worth entities as defined in article 49 of the FPO. This document should not be distributed or forwarded, either directly or indirectly, to any other individuals.

8. Miscellaneous

According to Article 4(1) No. i of the delegated regulation 2016/958 supplementing regulation 596/2014 of the European Parliament, further information regarding investment recommendations of the last 12 months are published under: www.nuways-ag.com

Date of publication creation: 29/01/2025 07:55 AM

Date of publication dissemination: 29/01/2025 07:55 AM

Update - 29.01.2025



Contacts

NuWays AG

Mittelweg 16-17 20148 Hamburg Germany +49 170 119 8648 info@nuways-ag.com www.nuways-ag.com



Christian Sandherr Co-CEO/Analyst

christian.sandherr@nuways-ag.com



Frederik Jarchow Co-CEO/Analyst

frederik.jarchow@nuways-ag.com



Philipp Sennewald

Analyst

philipp.sennewald@nuways-ag.com



Henry Wendisch

Analyst

henry.wendisch@nuways-ag.com



Mark Schüssler

Analyst

mark-hendrik.schuessler@nuways-ag.com



Konstantin Völk

Analyst

konstantin.voelk@nuways-ag.com

Find us on Social Media

Instagram



Twitter/X



<u>Linkedlı</u>

